Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 18/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913360 | 1.00 | MAOA (0.63) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5223522 | 0.94 | MAOA (0.60) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4918548 | 0.94 | MAOA (0.60) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4910356 | 0.92 | MAOA (0.66) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL14260823 | 0.92 | MAOA (0.61) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4915193 | 0.92 | MAOA (0.63) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4913242 | 0.91 | MAOA (0.59) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5433690 | 0.91 | MAOA (0.58) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4920366 | 0.90 | MAOA (0.62) | MAOACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4704542 | 0.89 | MAOA (0.69) | MAOACYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | claimed |
| EP-1753756-A1 | 3-¬4-(6-{4,5-DIHYDROISOXAZOL-3-YL}PYRIDIN-3-YL)-3-PHENYL|-5-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-1,3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | claimed |
| WO-2005116021-A1 | 3-[4-(6-{4,5-DIHYDROISOXAZOL-3-YL}PYRIDIN-3-YL)-3-PHENYL]-5-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-1,3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | claimed |
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| EP-1753756-A1 | 3-¬4-(6-{4,5-DIHYDROISOXAZOL-3-YL}PYRIDIN-3-YL)-3-PHENYL|-5-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-1,3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005116021-A1 | 3-[4-(6-{4,5-DIHYDROISOXAZOL-3-YL}PYRIDIN-3-YL)-3-PHENYL]-5-(1H-1,2,3-TRIAZOL-1-YLMETHYL)-1,3-OXAZOLIDIN-2-ONES AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064689-A1 | 3-[4-(6-Pyridin-3-Yl)-3-Phenyl] -5-(1H-1,2,3-Triazol-1-Ylmethyl)-1,3-Oxazolidin-2-Ones as Antibacterial Agents | H1-3, H1-0, MRPL21 | MAOA 2336/4885CYP3A4 420/4885CYP2D6 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.